| Characteristic | AstraZeneca/Oxford | Novavax | Biontech/Pfizer | Gamaleya | Moderna | Johnson & Johnson |
|---|---|---|---|---|---|---|
| India | 1,000 | 1,000 | - | 200 | - | - |
| European Union | 300 | - | 500 | - | 310 | 200 |
| United States | 300 | 110 | 300 | - | 300 | 100 |
| Covax | 300 | - | - | - | - | - |
| United Kingdom | 100 | 60 | 40 | - | 17 | 30 |
| Japan | 120 | - | 144 | - | 50 | - |
| Indonesia | 50 | 50 | - | - | - | - |
| Brazil | 100 | - | - | 100 | - | - |
| China | 200 | - | - | - | - | - |
| Canada | 20 | 52 | 40 | - | 44 | 10 |
| Mexico | 77 | - | 34 | 64 | - | - |
| Australia | 54 | 51 | 20 | - | - | - |
| Russia | - | - | - | 160 | - | - |
| Latin America bloc | 150 | - | - | - | - | - |
| South Korea | 20 | 40 | 26 | - | 40 | 4 |
March 2021
Worldwide
as of March 9, 2021
This is a selection of the most prominent vaccines (already approved or on track to be approved) and some countries/regions.
When country contracts include a range of doses to be purchased, we count the lower number. On Dec. 23, Canada’s contracts were updated to reflect those details verified by the government.The Latin America bloc covers all countries in the region except Brazil. The European Union bloc represents the 27 countries of the European Union. The Covax agreement extends to most countries in the world, including many in Africa that wouldn’t otherwise be covered. Jurisdictions without a population figure, such as Somalia and Syria, have been omitted. The Middle East bloc covers U.A.E., Egypt, Bahrain and Jordan. Partnerships involving local manufacturers are listed under the original vaccine developer.









